liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Vincristine in childhood leukaemia: No pharmacokinetic rationale for dose reduction in adolescents
Dept. of Women's/Children's Health, University Children's Hospital, Uppsala, Sweden.
Lönnerholm, G., Dept. of Women's/Children's Health, University Children's Hospital, Uppsala, Sweden, University Children's Hospital, SE-751 85 Uppsala, Sweden.
Department of Pharmacy, University Hospital, Groningen, Netherlands.
University Children's Hospital, Uppsala, Sweden, Queen Silvia Children's Hospital, Gothenburg, Sweden.
Show others and affiliations
2003 (English)In: Acta Paediatrica, ISSN 0803-5253, E-ISSN 1651-2227, Vol. 92, no 5, 551-557 p.Article in journal (Refereed) Published
Abstract [en]

Aim: To investigate whether there is any pharmacokinetic rationale for the common practice of administering vincristine to adolescents at relatively lower doses than those to younger children. Methods: A total of 98 children, aged 1.3-17.3 y, with acute lymphoblastic leukaemia (ALL) were studied on day 1 of induction therapy. Plasma samples were drawn before and 10, 30, 360 and 1380 min after injection of vincristine 2.0 mg/m2 (maximum dose 2.0 mg) and analysed by high-performance liquid chromatography. Results: The median value (and range) for distribution half-life was 6.4 min (0.8-11.8), elimination half-life 1014 min (258-2570), volume of distribution 445 L/m 2 (137-1241) and total body clearance 362 ml/min/m2 (134-2553). No correlation was found between age and any of these pharmacokinetic parameters. The area under the concentration time curve (AUC) was significantly correlated to age (p = 0.002, ?-0.31), as expected from the dosage of vincristine. The lower AUC in children with a body surface area > 1 m2, which is reached at 8-9 y of age, indicates that they received a less intense treatment because of the capping of the vincristine dose at 2.0 mg. Conclusions: Vincristine pharmacokinetics were not age dependent in this paediatric population. Thus, we found no pharmacokinetic rationale for dose reduction in adolescents. The common practice of limiting the vincristine dose to 2.0 mg should be carefully reconsidered.

Place, publisher, year, edition, pages
2003. Vol. 92, no 5, 551-557 p.
Keyword [en]
Acute lymphoblastic leukaemia, Children, Pharmacokinetics, Vincristine
National Category
Natural Sciences
Identifiers
URN: urn:nbn:se:liu:diva-46642DOI: 10.1080/08035350310011470OAI: oai:DiVA.org:liu-46642DiVA: diva2:267538
Available from: 2009-10-11 Created: 2009-10-11 Last updated: 2012-01-07

Open Access in DiVA

No full text

Other links

Publisher's full text
By organisation
Department of Paediatrics MH
In the same journal
Acta Paediatrica
Natural Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 40 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf